Table 3.
Risk of colorectal cancer and molecular subgroups in relation to HRT and ERT use
| Tumour subgroups | HRT use | n | HR crude | p | HR adjusted | p |
|---|---|---|---|---|---|---|
| beta-catenin + |
No |
126 |
1.00 |
|
1.00 |
|
| ERT |
13 |
0.93(0.52-1.64) |
0.790 |
1.04(0.58-1.84) |
0.902 |
|
| CHRT |
19 |
0.64(0.40-1.04) |
0.074 |
0.87(0.53-1.42) |
0.868 |
|
| beta-catenin − |
No |
80 |
1.00 |
|
1.00 |
|
| ERT |
7 |
0.76(0.35-1.65) |
0.490 |
0.77(0.36-1.68) |
0.516 |
|
| CHRT |
13 |
0.69(0.39-1.24) |
0.217 |
0.83(0.46-1.50) |
0.533 |
|
| cyclin D1 + |
No |
173 |
1.00 |
|
1.00 |
|
| ERT |
16 |
0.81(0.49-1.35) |
0.416 |
0.87(0.52-145) |
0.591 |
|
| CHRT |
29 |
0.72(0.48-1.06) |
0.096 |
0.93(0.63-1.39) |
0.734 |
|
| cyclin D1 − |
No |
31 |
1.00 |
|
1.00 |
|
| ERT |
4 |
1.16(0.41-3.28) |
0.782 |
1.26(0.44-3.59) |
0.661 |
|
| CHRT |
5 |
0.68(0.27-1.75) |
0.425 |
0.84(0.32-2.19) |
0.721 |
|
| p53 + |
No |
99 |
1.00 |
|
1.00 |
|
| ERT |
11 |
0.98(0.53-1.83) |
0.956 |
1.07(0.57-1.99) |
0.843 |
|
| CHRT |
18 |
0.78(0.47-1.29) |
0.334 |
1.00(0.59-1.65) |
0.970 |
|
| p53 − |
No |
107 |
1.00 |
|
1.00 |
|
| ERT |
9 |
0.74(0.37-1.45) |
0.374 |
0.79(0.40-1.55) |
0.488 |
|
| CHRT |
16 |
0.63(0.38-1.07) |
0.089 |
0.84(0.49-1.42) |
0.508 |
|
| MSI |
No |
38 |
1.00 |
|
1.00 |
|
| ERT |
1 |
0.23(0.03-1.63) |
0.140 |
0.24(0.03-1.72) |
0.154 |
|
| CHRT |
5 |
0.56(0.22-1.43) |
0.225 |
0.80(0.31-2.06) |
0.649 |
|
| MSS | No |
164 |
1.00 |
|
1.00 |
|
| ERT |
18 |
0.97(0.60-1.58) |
0.903 |
1.06(0.65-1.72) |
0.829 |
|
| CHRT | 28 | 0.73(0.49-1.09) | 0.120 | 0.92(0.61-1.39) | 0.700 |
Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.